• 1
    American Cancer Society. Cancer facts & figures 2007. Available at: Accessed October 2, 2007.
  • 2
    The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997; 89: 39093918.
  • 3
    Harris NL,Jaffe ES,Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 13611392.
  • 4
    Zucca E,Fontana S,Roggero E,Pedrinis E,Pampallona S,Cavalli F. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma. 1994; 13: 105110.
  • 5
    Velders GA,Kluin-Nelemans JC,De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996; 14: 12691274.
  • 6
    Pittaluga S,Bijnens L,Teodorovic I, et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood. 1996; 87: 43584367.
  • 7
    Argatoff LH,Connors JM,Klasa RJ,Horsman DE,Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997; 89: 20672078.
  • 8
    Ko YH,Kim CW,Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998; 83: 806812.
  • 9
    Ohshima K,Suzumiya J,Sato K,Kanda M,Haraoka S,Kikuchi M. B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Lett. 1999; 135: 7381.
  • 10
    Naresh KN,Advani S,Adde M, et al. Report of an International Network of Cancer Treat Research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol Dis. 2004; 33: 330337.
  • 11
    Naresh KN,Srinivas V,Soman CS. Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol. 2000; 11( suppl 1): 6367.
  • 12
    Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000; 50: 696702.
  • 13
    Chuang SS,Lin CN,Li CY. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer. 2000; 89: 15861592.
  • 14
    Andersen NS,Jensen MK,de Nully Brown P,Geisler CH. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer. 2002; 38: 401408.
  • 15
    Economopoulos T,Papageorgiou S,Dimopoulos MA, et al. Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. Acta Haematol. 2005; 113: 97103.
  • 16
    Turner JJ,Hughes AM,Kricker A, et al. Use of the WHO lymphoma classification in a population-based epidemiological study. Ann Oncol. 2004; 15: 631637.
  • 17
    Rappaport H, Winter WJ,Hicks EB. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer. 1956; 9: 792821.
  • 18
    Lennert K,Stein H. Histopathology of Non-Hodgkin's Lymphomas: Based on the Kiel Classification. New York, NY: Springer-Verlag; 1981.
  • 19
    Weisenburger DD,Kim H,Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982; 49: 14291438.
  • 20
    Jaffe ES,Bookman MA,Longo DL. Lymphocytic lymphoma of intermediate differentiation–mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol. 1987; 18: 877880.
  • 21
    The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982; 49: 21122135.
  • 22
    Banks PM,Chan J,Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992; 16: 637640.
  • 23
    Swerdlow SH,Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002; 33: 720.
  • 24
    Jaffe ES,Harris NL,Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Heamatopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
  • 25
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence–Seer 13 Regs Limited-Use, Nov 2006 Sub (1992–2004)–Linked to County Attributes–Total U.S., 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. Available at URL:
  • 26
    Fritz A,Rics L, eds. SEER Extent of Disease 1998, Codes and Coding Instructions (No. T-899; Pub. No. 98-4354). 3rd ed. Bethesda, MD: Cancer Statistics Branch, Surveillance Program, Division of Cancer Control and Population Sciences, National Cancer Institute, US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998;1: 7.
  • 27
    The Surveillance Research Program of the Division of Cancer Control and Population Sciences, National Cancer Institute. Surveillance Research Program. SEER Stat Software, version 6.3.6. Bethesda, MD: National Cancer Institute. Available at URL:
  • 28
    Chu KC,Miller BA,Feuer EJ,Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994; 47: 14511461.
  • 29
    National Cancer Institute. SEER*Stat statistical methods for incidence and mortality. Available at Accessed June 11, 2007.
  • 30
    Clarke CA,Undurraga DM,Harasty PJ,Glaser SL,Morton LM,Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 630638.
  • 31
    Morton LM,Wang SS,Devesa SS,Hartge P,Weisenburger DD,Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265276.
  • 32
    Clarke CA,Glaser SL,Dorfman RF,Bracci PM,Eberle E,Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004; 13: 138143.
  • 33
    Gurney KA,Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J. 2002; 3: 95104.
  • 34
    Zeeb H,Blettner M. Increasing incidence and mortality of non-Hodgkin lymphomas. An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma [in German]. Med Klin (Munich). 2001; 96: 87100.
  • 35
    Bhurgri Y,Pervez S,Bhurgri A, et al. Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev. 2005; 6: 364369.
  • 36
    Sandin S,Hjalgrim H,Glimelius B,Rostgaard K,Pukkala E,Askling J. Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev. 2006; 15: 12951300.
  • 37
    Foran JM,Cunningham D,Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000; 11( suppl 1): 117121.
  • 38
    Zhou Y,Zhang L,Romaguera J, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008; 83: 144149.
  • 39
    Romaguera JE,Fayad L,Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 70137023.
  • 40
    Goy A,Younes A,McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667675.
  • 41
    Wang M,Han XH,Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008; 22: 179185.
  • 42
    Villanueva ML,Vose JM. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2006; 4: 521530.